410 related articles for article (PubMed ID: 34494957)
1. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.
Nash P; Mease PJ; Kirkham B; Singhal A; Quebe-Fehling E; Pricop L; Gaillez C
Clin Exp Rheumatol; 2022 May; 40(5):952-959. PubMed ID: 34494957
[TBL] [Abstract][Full Text] [Related]
2. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M
Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.
Mease PJ; Landewé R; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Readie A; Mpofu S; Delicha EM; Pricop L; van der Heijde D
RMD Open; 2021 Jul; 7(2):. PubMed ID: 34330846
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study.
Kirkham B; Nash P; Reina D; Navarra S; Quebe-Fehling E; Gaillez C; Sastre C; Mease PJ
Clin Exp Rheumatol; 2023 Mar; 41(3):589-596. PubMed ID: 35916290
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.
van der Heijde D; Mease PJ; Landewé RBM; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Zhu X; Ligozio G; Readie A; Mpofu S; Pricop L
Rheumatology (Oxford); 2020 Jun; 59(6):1325-1334. PubMed ID: 31586420
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
[TBL] [Abstract][Full Text] [Related]
7. Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension.
D'Agostino MA; Carron P; Gaillez C; Conaghan PG; Naredo E; López-Rdz A; Šenolt L; Burgos-Vargas R; Hanova P; Padovano I; Cazenave T; Stoenoiu MS; Backhaus M; Mouterde G; Bao W; Goyanka P; Boers M; Schett G
Semin Arthritis Rheum; 2023 Dec; 63():152259. PubMed ID: 37660536
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
Reich K; Baraliakos X; Coates LC; Elewski B; Bao W; Kasparek T; Gaillez C; Pournara E; Aassi M; Perella C; Gottlieb AB
Br J Dermatol; 2022 Sep; 187(3):438-441. PubMed ID: 35257363
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab efficacy in the treatment of nail psoriasis: a case series.
Pistone G; Gurreri R; Tilotta G; Castelli E; Bongiorno MR
J Dermatolog Treat; 2018; 29(sup1):21-24. PubMed ID: 30273068
[TBL] [Abstract][Full Text] [Related]
10. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
Kokolakis G; Vadstrup K; Hansen JB; Carrascosa JM
Dermatology; 2022; 238(4):620-629. PubMed ID: 34823247
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study.
Mease P; Elaine Husni M; Chakravarty SD; Kafka S; Parenti D; Kim L; Hung Lo K; Hsia EC; Kavanaugh A
ACR Open Rheumatol; 2020 Nov; 2(11):640-647. PubMed ID: 33073933
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P; van der Heijde D; Landewé R; Mpofu S; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Meiser K; Readie A; Pricop L; Abrams K
Ann Rheum Dis; 2018 Jun; 77(6):890-897. PubMed ID: 29550766
[TBL] [Abstract][Full Text] [Related]
14. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis.
Wells LE; Evans T; Hilton R; Wine Lee L; Ruth N
Pediatr Dermatol; 2019 May; 36(3):384-385. PubMed ID: 30811618
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.
Kavanaugh A; Mease PJ; Reimold AM; Tahir H; Rech J; Hall S; Geusens P; Wang Z; Pricop L; Mpofu S;
Arthritis Care Res (Hoboken); 2017 Mar; 69(3):347-355. PubMed ID: 27696786
[TBL] [Abstract][Full Text] [Related]
16. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.
Reich K; Sullivan J; Arenberger P; Jazayeri S; Mrowietz U; Augustin M; Elewski B; You R; Regnault P; Frueh JA
Br J Dermatol; 2021 Mar; 184(3):425-436. PubMed ID: 32479641
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
